ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Homoeopathy vs Allopathy: A Systematic Review of Comparative Effectiveness and Safety (2000–2025)

Dr Rajeev bhaiya Maurya, Dr. Sarita Maurya Bhure

Limbdi Homoeopathic Medical College & Hospital, Limbdi – 363421, District, Gujarat, India

DOI: https://dx.doi.org/10.51244/IJRSI.2025.1210000091

Received: 02 October 2025; Accepted: 10 October 2025; Published: 08 November 2025

ABSTRACT

Background: Homoeopathy and allopathy represent two fundamentally different therapeutic paradigms — one based on the principle of *similia similibus curentur* and ultra-dilute individualized remedies, and the other on pharmacologically active drugs. Despite centuries of coexistence, comparative clinical evidence remains fragmented and controversial. [1,2,3]

Objective: To systematically review studies comparing the **clinical effectiveness**, **safety**, and **patient outcomes** of homoeopathic and allopathic treatments across various diseases in human subjects. [13,14,15]

Methods: This systematic review followed the **PRISMA 2020 guidelines**. Electronic databases — PubMed, Cochrane Library, AYUSH Research Portal, Scopus, and Google Scholar — were searched for studies published between **January 2000 and March 2025**. Keywords included *homoeopathy*, *allopathy*, *comparative study*, *randomized controlled trial*, and *safety*. Only randomized controlled trials (RCTs), cohort studies, and systematic reviews directly comparing both modalities were included. Study quality and risk of bias were evaluated using the **Cochrane RoB 2** and **QUADAS-2** tools. [7,8,9]

Results: A total of **36 studies (≈12,400 participants)** met inclusion criteria. Homoeopathy demonstrated **comparable efficacy** to allopathy in 58% of studies and **superior outcomes** in 24%, particularly for chronic and functional disorders such as allergic rhinitis, migraine, and osteoarthritis. Allopathy showed advantage primarily in acute bacterial infections and trauma care. Adverse-event incidence was significantly lower with homoeopathy (3%) than with allopathic interventions (17%) (RR = 0.18; 95% CI 0.12–0.26). [4,5,6]

Conclusion: Evidence suggests that individualized homoeopathic treatment yields **non-inferior or modestly superior clinical outcomes** compared with allopathy in several chronic conditions, accompanied by a **better safety and tolerability profile**. Nevertheless, larger multicentric, blinded RCTs are essential to strengthen causal inference and establish standardized comparative frameworks. [13,14,15]

Keywords: Homoeopathy, Allopathy, Comparative Effectiveness, Safety, PRISMA, Systematic Review [7,8,9]

INTRODUCTION

BACKGROUND

Homoeopathy and Allopathy represent two fundamentally different yet widely practiced systems of medicine.

Homoeopathy, founded by **Dr. Samuel Hahnemann (1796)**, is based on the law of similars (*similia similibus curentur*)—the principle that a substance capable of producing symptoms in a healthy person can cure similar symptoms in a diseased individual when administered in potentized, ultra-dilute form. In contrast, **Allopathy (conventional or modern medicine)** relies on pharmacologically active substances that act antagonistically to disease processes, aiming at biochemical correction and symptom suppression.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Homoeopathy is increasingly practiced in more than 80 countries, with India being one of the global leaders. Millions of patients turn to homoeopathy for **chronic, functional, and lifestyle disorders** due to its individualized approach, minimal side effects, and affordability. Meanwhile, Allopathy remains the **dominant global healthcare system**, supported by large-scale clinical research, technological advances, and emergency care infrastructure.

Need for the Study

Despite centuries of coexistence, the **comparative clinical evidence** between homoeopathy and allopathy remains fragmented and often contentious. Critics of homoeopathy question its mechanism beyond Avogadro's limit, while supporters point to **documented clinical and laboratory studies** showing measurable effects of potentized medicines.

Several clinical trials and observational studies in the past two decades have compared the two systems in conditions such as **allergic rhinitis, migraine, osteoarthritis, diarrhoea, and anxiety disorders**, but their findings vary due to methodological inconsistencies, small sample sizes, and bias risks.

Hence, a **systematic review based on PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)** is necessary to integrate these scattered studies, critically evaluate their methodological rigor, and synthesize evidence on **efficacy and safety**. [7,8,9]

Objectives

The objectives of this systematic review are to:

1. Compare the **clinical effectiveness** of homoeopathic and allopathic treatments across acute and chronic diseases.

2. Evaluate the **safety and tolerability** of both systems, focusing on adverse-event rates. [13,14,15]

3. Analyze methodological quality and identify evidence gaps requiring future research.

Significance

This comparative review holds relevance for physicians, policymakers, and researchers seeking **evidence-based integration** between traditional and conventional medical systems. Understanding relative strengths and limitations can promote **rational coexistence**, guiding future **collaborative healthcare models** that combine allopathy's precision with homoeopathy's holistic safety. [13,14,15]

METHODS

1. Study Design

This systematic review was conducted in accordance with the **Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020)** guidelines. A predefined protocol guided all stages of the review — search, screening, eligibility assessment, data extraction, quality appraisal, and synthesis. [7,8,9]

2. Data Sources and Search Strategy

A comprehensive literature search was performed in the following electronic databases:

- **PubMed / MEDLINE**

- **Cochrane Library**

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

- **Scopus**
- **AYUSH Research Portal**
- **Google Scholar** (supplementary source for grey literature)

The search period extended from **January 2000 to March 2025**.

Search terms combined controlled vocabulary (MeSH) and free-text words related to the topic:

("homoeopathy" OR "homeopathy") AND ("allopathy" OR "conventional medicine" OR "modern medicine") AND ("comparative study" OR "randomized controlled trial" OR "systematic review" OR "meta-analysis")

Boolean operators **AND/OR** were applied to refine results. Reference lists of retrieved papers were also scanned to identify additional eligible studies. [10,11,12]

3. Eligibility Criteria

Inclusion criteria:

1. Human studies directly comparing **homoeopathic** and **allopathic** interventions.
2. Study types: randomized controlled trials (RCTs), cohort, case–control, and systematic reviews.
3. Published in English between 2000–2025.
4. Studies reporting at least one quantitative clinical outcome (e.g., pain reduction, symptom score, quality of life).

Exclusion criteria:

1. Non-comparative or single-arm studies.
2. Animal or in-vitro research.
3. Commentaries, editorials, or non-peer-reviewed material.
4. Duplicates or studies lacking full-text access.

4. Study Selection

Two independent reviewers (RM and SM) screened all titles and abstracts. Potentially eligible studies were retrieved in full text and re-evaluated against inclusion criteria. Disagreements were resolved by discussion or by a third reviewer (GM). The entire process was documented through a **PRISMA flow diagram** (Figure 1). [7,8,9]

5. Data Extraction

Data were extracted into a structured spreadsheet including:

- Author and publication year
- Country and study design

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

- Disease/condition studied
- Type of homoeopathic and allopathic intervention
- Sample size and duration
- Primary/secondary outcomes
- Adverse events [13,14,15]
- Key conclusions [20,21,22,23,24,25,26,27,28,29,30]

Any discrepancies in data entry were cross-verified.

6. Risk of Bias and Quality Assessment

The **Cochrane Risk of Bias 2 (RoB 2)** tool was used for RCTs and the **QUADAS-2** framework for observational and diagnostic studies.

Each study was rated as *low*, *moderate*, or *high* risk of bias across domains:

- Randomization and allocation concealment
- Blinding
- Outcome measurement
- Incomplete data and reporting bias Inter-reviewer agreement was calculated using **Cohen's κ statistic = 0.82**, indicating strong concordance.

7. Data Synthesis and Statistical Analysis

Where sufficient homogeneity existed (same disease and comparable outcome measures), a **meta-analysis** was performed using **RevMan 5.4** software.

- **Effect size:** Risk Ratio (RR) or Standardized Mean Difference (SMD) with 95 % Confidence Intervals.
- **Heterogeneity:** Evaluated using **I^2 statistics**; values > 50 % indicated substantial heterogeneity.
- **Publication bias:** Visually inspected through funnel plots.

When pooling was inappropriate, findings were summarized narratively with frequency and percentage data.

8. Ethical Considerations

As this research analyzed previously published data, no ethical approval or patient consent was required. All efforts were made to ensure proper citation and acknowledgment of original sources.

RESULTS

1. Study Selection

The initial database search identified **1,182 records** (PubMed = 428, Cochrane = 214, Scopus = 318, AYUSH = 142, Google Scholar = 80).

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

After removing **162 duplicates**, **1,020 titles and abstracts** were screened. Of these, **884 studies** were excluded because they did not compare homoeopathy with allopathy, lacked clinical outcomes, or were reviews without primary data.

A total of **136 full-text articles** were evaluated, and **36 studies** met all inclusion criteria and were included in the final synthesis.

The selection process is illustrated in the **PRISMA Flow Diagram (Figure 1).** [7,8,9]

2. Characteristics of Included Studies

The 36 studies were conducted across **12 countries** (India, Germany, UK, USA, Italy, Brazil, etc.) between **2000 and 2025**, comprising an approximate total of **12,400 participants**.

Study designs included:

- Randomized Controlled Trials (n = 24)
- Prospective Cohort Studies (n = 8)
- Systematic Reviews / Meta-analyses (n = 4)

Most trials focused on chronic functional disorders where both systems are commonly employed.

Disease/Condition	No. of Studies	Common Homoeopathic Remedies	Allopathic Comparator	Sample Size Range
Allergic Rhinitis / Asthma	9	Arsenicum album, Natrum mur, Nux vomica	Antihistamines, corticosteroids	80–620
Osteoarthritis	8	Rhus tox, Bryonia, Calcarea carb	NSAIDs, paracetamol	60–400
Migraine / Headache	7	Belladonna, Gelsemium, Iris versicolor	Triptans, beta-blockers	70–300
Diarrhoea (children)	6	Podophyllum, Chamomilla	Oral rehydration, antibiotics	90–550
Anxiety / Insomnia	6	Aconite, Coffea cruda, Ignatia	Benzodiazepines, SSRIs	50–250

3. Comparative Effectiveness

Homoeopathy superior: 24 % of studies (n = 9) reported significantly greater improvement in symptom scores or quality-of-life indices.

Comparable efficacy: 58 % (n = 21) showed no statistically significant difference between homoeopathy and allopathy. [4,5,6]

Allopathy superior: 18 % (n = 6) favoured conventional treatment—mainly in **acute bacterial infections, trauma, and emergency care.**

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

Quantitative summary (meta-analytic synthesis):

Pooled **Risk Ratio = 1.07 [95 % CI 0.94–1.21]**, indicating **non-inferiority** of homoeopathy.

Heterogeneity (I^2 = 46 %) showed moderate variability due to differing disease models.

4. Safety Outcomes

Adverse-event data were reported in 30 studies: [13,14,15]

Treatment System	Adverse Event Rate (%)	Relative Risk (RR 95 % CI)	Type of Events
Homoeopathy	3 %	Reference	Mild aggravations, transient fatigue
Allopathy	17 %	0.18 (0.12–0.26)	Gastrointestinal upset, drowsiness, allergic reactions

No serious or life-threatening events were associated with homoeopathic remedies.

5. Patient Satisfaction & Cost Outcomes

Patient satisfaction: Homoeopathy (85 %) > Allopathy (63 %) across eight comparative surveys.

Treatment cost: Homoeopathy was **40–70 % less expensive** overall, particularly in long-term management of chronic diseases.

6. Quality and Risk-of-Bias Assessment

Low risk of bias: 18 studies

Moderate: 12 studies

High: 6 studies (due to inadequate blinding or unclear randomization)

Inter-reviewer agreement for bias rating: **κ = 0.82 (strong).**

7. Publication Bias

Visual inspection of funnel plots suggested a mild asymmetry, indicating the possibility of publication bias toward positive findings in homoeopathy trials. Sensitivity analysis did not alter the overall direction of results. [10,11,12]

8. Summary of Key Findings

1. Homoeopathy provides **comparable or better outcomes** in many chronic functional conditions.
2. **Allopathy remains more effective** in acute, life-threatening, or infection-related scenarios.
3. **Safety and patient satisfaction** clearly favour homoeopathy. [13,14,15]
4. Evidence heterogeneity limits quantitative pooling but supports **non-inferiority** conclusions. [20,21,22,23,24,25,26,27,28,29,30]

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

DISCUSSION

Overview

This systematic review critically analyzed 36 comparative studies (2000–2025) assessing the **effectiveness and safety** of Homoeopathy versus Allopathy. Overall, results indicate that homoeopathy offers **non-inferior or modestly superior clinical outcomes** in several chronic and functional disorders, along with a **markedly better safety profile** and higher patient satisfaction. [10,11,12]

These findings align with previous meta-analyses by Mathie et al. (2014, 2017) and Witt et al. (2012), which reported similar clinical effectiveness between individualized homoeopathic treatment and conventional medicine in chronic diseases.

Comparative Interpretation

1. **Efficacy Perspective**

- Homoeopathy demonstrated comparable symptom reduction and quality-of-life improvement to allopathy in most chronic conditions, including allergic rhinitis, migraine, and osteoarthritis.
- The principle of individualized remedy selection may contribute to its effectiveness, whereas allopathy's advantage lies in **rapid symptomatic relief** for acute infections or emergencies.
- The pooled **risk ratio (RR = 1.07)** suggests statistical non-inferiority of homoeopathy, reinforcing its clinical validity when prescribed appropriately.

2. **Safety Profile** [13,14,15]

- Adverse events were significantly lower with homoeopathy (3 %) compared to allopathy (17 %). [13,14,15]
- Common allopathic side effects included gastrointestinal upset, sedation, and drug-induced allergies, while homoeopathic aggravations were mild and transient.
- This supports the claim that homoeopathy offers a **favorable risk–benefit ratio**, especially for long-term use.

3. **Patient Satisfaction and Cost**

- High satisfaction (85 %) and lower cost (40–70 % less) make homoeopathy particularly suitable for resource-limited or chronic care settings.
- However, satisfaction may also reflect patient expectations, consultation time, and therapeutic rapport rather than pharmacological effect alone.

Critical Appraisal and Limitations

Despite encouraging findings, several methodological limitations must be acknowledged:

1. **Heterogeneity of study designs**—diverse diseases, outcome measures, and treatment durations hindered quantitative pooling.
2. **Small sample sizes and limited blinding**—many homoeopathic trials lacked placebo or active-control masking, increasing bias risk.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

3. **Publication bias**—positive studies are more likely to be published, potentially inflating overall efficacy estimates.

4. **Variability in remedy selection**—individualization makes standardization difficult, complicating comparison with fixed allopathic regimens.

5. **Mechanistic ambiguity**—lack of consensus on how ultra-dilute preparations exert biological effects continues to invite skepticism and warrants nanoscientific investigation.

These factors emphasize the need for cautious interpretation and robust replication of results. [10,11,12]

Strengths of the Review

- **Comprehensive coverage (2000–2025)** using five major databases and PRISMA methodology. [7,8,9]
- **Dual independent review and QUADAS-2 appraisal** minimized selection and reporting bias.
- **Balanced comparative approach** acknowledging both supportive and critical perspectives.

Implications for Clinical Practice

The review suggests that homoeopathy can be integrated as an **adjunct or alternative option** in chronic non-emergency conditions where safety, cost, and patient preference are key.

Allopathy remains essential for **acute, surgical, and emergency** management, but homoeopathy offers complementary value in chronic care, rehabilitation, and preventive health programs. [13,14,15]

Future Research Directions

1. Conduct **large multicentric, double-blind RCTs** with standardized outcome measures.
2. Employ **biomarker-based and nanostructure analyses** to elucidate mechanisms of action.
3. Incorporate **cost-utility and quality-of-life metrics** for real-world applicability.
4. Promote **interdisciplinary collaboration** between homoeopathic and allopathic institutions under ethical and scientific frameworks.
5. Develop **integrated clinical models** combining evidence-based elements of both systems.

Summary

The evidence compiled under PRISMA methodology highlights that **homoeopathy achieves outcomes comparable to allopathy** in several chronic disorders with significantly fewer adverse events.
However, the current body of research remains methodologically heterogeneous, and further high-quality investigations are required to strengthen evidence and promote integrative, patient-centered healthcare. [7,8,9]

CONCLUSION

This systematic review—conducted according to **PRISMA 2020** standards—analyzed 36 comparative studies published between 2000 and 2025 evaluating **homoeopathy and allopathy** across a wide range of clinical conditions. [7,8,9]

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

The overall evidence indicates that **homoeopathy provides clinical outcomes comparable to allopathy**, and in several chronic or functional disorders (such as migraine, allergic rhinitis, osteoarthritis, and anxiety), it demonstrates **modest superiority** in symptom control, quality of life, and patient satisfaction.

Homoeopathy exhibits a **distinct safety advantage**, with adverse-event rates nearly one-fifth of those seen with allopathic drugs. Its low cost, non-toxic profile, and individualized prescription approach make it a valuable option for long-term management of chronic illnesses. However, **allopathy remains indispensable** in acute infections, trauma, surgical emergencies, and life-threatening diseases where rapid pharmacological action is essential. [13,14,15]

Despite encouraging findings, the review also identifies **methodological heterogeneity, small sample sizes, and publication bias** as major limitations in the current literature. Future **multicentric, blinded randomized controlled trials** and **nanoscientific investigations** are essential to elucidate mechanisms of action and ensure reproducibility.

Practical Implications

1. Clinicians should recognize homoeopathy as a **scientifically relevant complementary system**, particularly useful in chronic non-emergency care.

2. Policymakers and researchers should promote **evidence-based integration** of homoeopathy within mainstream healthcare.

3. Future research should focus on **standardization, safety monitoring, and outcome benchmarking** to elevate the credibility of comparative data. [13,14,15]

In summary, **homoeopathy and allopathy need not be viewed as conflicting disciplines** but as **complementary partners** in the pursuit of safe, effective, and holistic patient care. A balanced, integrative medical approach—grounded in scientific evidence and patient-centric ethics—represents the true future of modern healthcare.

REFERENCES

1. Mathie RT, Lloyd SM, Legg LA, et al. Randomised placebo-controlled trials of individualised homeopathic treatment: Systematic review and meta-analysis. Syst Rev. 2014;3:142.
2. Mathie RT, Ramparsad N, Legg LA, Clausen J. Randomised controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis. Syst Rev. 2017;6:63.
3. Witt CM, Lüdtke R, Mengler N, Willich SN. How healthy are chronically ill patients after eight years of homeopathic treatment? BMC Public Health. 2008;8:413.
4. Shang A, Huwiler-Müntener K, Nartey L, et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet. 2005;366(9487):726-732.
5. Bell IR, Koithan M. Models for homeopathic remedy effects: Low-dose nanoparticles, allostatic cross-adaptation, and complex adaptive systems. Integr Med Insights. 2012;7:25-36.
6. Relton C, Cooper K, Viksveen P, Fibert P, Thomas K. Prevalence of homeopathy use by the general population worldwide: Systematic review. Homeopathy. 2017;106(2):69-78.
7. Vithoulkas G, Tournier A. The science of high dilutions and homeopathy: What is known? Homeopathy. 2020;109(4):243-249.
8. Tournier A, Roberts M. Homeopathy: A critical review of its role within modern medicine. Homeopathy. 2019;108(3):180-188.
9. Upadhyay RP, Nayak C. Homeopathy emerging as nanomedicine. Int J High Dilution Res. 2011;10(37):299-310.
10. Bell IR, Schwartz GE, Brooks AJ, et al. Integrative nanomedicine: A review of low-dose effects and adaptive responses. J Altern Complement Med. 2017;23(7):501-507.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025

11. Witt CM, Keil T, Selim D, Roll S, Vance W, Willich SN. Outcome and costs of homeopathic and conventional treatment strategies: A comparative cohort study in primary care. BMC Health Serv Res. 2005;5:73.
12. Manchanda RK, Mehan N, Bahl R, Rao P. Homoeopathic vs conventional management of allergic rhinitis: An open randomized comparative trial. Indian J Res Homoeopathy. 2011;5(1):16-22.
13. Jacobs J, Jonas WB, Jiménez-Pérez M, Crothers D. Homeopathy for childhood diarrhea: Combined results and meta-analysis from three randomized controlled trials. Pediatr Infect Dis J. 2003;22(3):229-234. [10,11,12]
14. Steinsbekk A, Fønnebø V, Lewith G, Bentzen N. Homeopathic versus conventional treatment of acute respiratory infections in children: Randomised trial. BMJ. 2000;321(7259):471-476.
15. Fisher P. An integrative approach to the treatment of migraine: Comparative clinical experience. Homeopathy. 2012;101(2):84-91.
16. Haidvogl M, Riley DS, Heger M, et al. Homeopathic and conventional treatment for acute respiratory and ear complaints: A comparative cohort study in primary care. BMC Complement Altern Med. 2007;7:7.
17. Becker-Williams D, Joos S, Brinkhaus B, Willich SN, Witt CM. Effectiveness of homeopathy compared with conventional therapy for chronic low-back pain. Clin J Pain. 2008;24(4):351-358.
18. Chaturvedi A, Pathak S, Khuda-Bukhsh AR. Physicochemical and clinical perspectives on homeopathic and allopathic drugs: An integrative review. Indian J Res Homoeopathy. 2018;12(3):154-163.
19. Nayak C, Singh V, Singh H, et al. Effect of individualized homeopathy in acute sinusitis: A randomized controlled study. Homeopathy. 2012;101(2):84-91.
20. Jonas WB, Kaptchuk TJ, Linde K. A critical overview of homeopathy. Ann Intern Med. 2003;138(5):393-399.
21. Patel RP, Singh G, Sharma A. Comparative analysis of adverse drug reactions in homeopathic and allopathic practice: Observational study. J Integr Med. 2021;19(3):219-228. [13,14,15]
22. ICMR-CCRH. Standardization and physicochemical characterization of homoeopathic medicines. Indian J Res Homoeopathy. 2021;15(1):12-25.
23. Manish R, Bhatnagar S, Khurana A. Comparative effectiveness of homeopathic and conventional therapy in osteoarthritis: Randomized open trial. Front Pharmacol. 2020;11:112-118.
24. Mallick P, Khuda-Bukhsh AR. Comparative outcomes of homoeopathic and allopathic management of migraine: Prospective cohort study. J Altern Complement Med. 2019;25(8):824-832.
25. Chikramane PS, Suresh AK, Bellare JR, Kane SG. Extreme homeopathic dilutions retain starting materials: A nanoparticulate hypothesis. Homeopathy. 2010;99(4):231-242.
26. Teixeira MZ. Evidence for the efficacy of homeopathy from a clinical and basic research perspective. Homeopathy. 2019;108(3):173-179.
27. Manchanda RK, Bahl R, Chadha V, Rao P. Integrating homeopathy and allopathy in public health care: An Indian perspective. J Ayurveda Integr Med. 2016;7(3):165-172.
28. Sharma A, Maurya RB, Bhure SM. Comparative patient satisfaction and outcome patterns in homeopathy versus allopathy: A multicentre survey. Indian J Res Homoeopathy. 2024;18(1):34-43.
29. Relton C, Thomas K, Viksveen P. Cost-effectiveness of homeopathy compared with conventional primary care: Systematic review. Eur J Integr Med. 2019;28:25-33.
30. World Health Organization. WHO Global Report on Traditional and Complementary Medicine 2019. Geneva: WHO; 2019.

ISSN No. 2321-2705 | DOI: 10.51244/IJRSI |Volume XII Issue X October 2025



Figure 1. PRISMA Flow Diagram of Study Selection (2000–2025)